A new view of ras isoforms in cancers

Cancer Research

Volumn 76, Issue 1, 2016, Pages 18-23

  Nussinov, Ruth ^a,b   Tsai, Chung Jung ^a   Chakrabarti, Mayukh ^a,c   Jang, Hyunbum ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN; H RAS PROTEIN; K RAS4A PROTEIN; K RAS4B PROTEIN; N RAS PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; ISOPROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; CARBOXY TERMINAL SEQUENCE; COLORECTAL CANCER; COLORECTAL CARCINOMA; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; MOLECULAR MODEL; NEOPLASM; ONCOGENE RAS;

ANIMALS; GENES, RAS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN ISOFORMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84957890940     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1536     Document Type: Review

References (33)

1. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases 2010;1: 2-27.
2. Fetics SK, Guterres H, Kearney BM, Buhrman G, Ma B, Nussinov R, et al. Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 2015;23:505-16.
3. Tsai FD, Lopes MS, Zhou M, Court H, Ponce O, Fiordalisi JJ, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membranetargeting motif. Proc Natl Acad Sci U S A 2015;112:779-84.
4. Roy S, Plowman S, Rotblat B, Prior IA, Muncke C, Grainger S, et al. Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling. Mol Cell Biol 2005;25:6722-33.
5. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 2014;13:828-51.
6. Cox AD, Der CJ, Philips MR. Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin Cancer Res 2015;21: 1819-27.
7. Laude AJ, Prior IA. Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain. J Cell Sci 2008;121:421-7.
8. Jang H, Abraham SJ, Chavan TS, Hitchinson B, Khavrutskii L, Tarasova NI, et al. Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region. J Biol Chem 2015;290:9465-77.
9. Abankwa D, Gorfe AA, Inder K, Hancock JF. Ras membrane orientation and nanodomain localization generate isoformdiversity. Proc Natl Acad SciUS A 2010;107:1130-5.
10. Shoemaker SD, Vanderlick TK. Intramembrane electrostatic interactions destabilize lipid vesicles. Biophys J 2002;83:2007-14.
11. Muratcioglu S, Chavan TS, Freed BC, Jang H, Khavrutskii L, Freed RN, et al. GTP-dependent K-Ras dimerization. Structure 2015;23:1325-35.
12. Resh MD. Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol 2006;2:584-90.
13. Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005;106:2113-9.
14. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res 2007;67: 7139-46.
15. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 2008;40:1240-4.
16. Villalonga P, Lopez-Alcala C, Bosch M, Chiloeches A, Rocamora N, Gil J, et al. Calmodulin binds to K-Ras, but not to H- or N-Ras, andmodulates its downstream signaling. Mol Cell Biol 2001;21:7345-54.
17. Lopez-Alcala C, Alvarez-Moya B, Villalonga P, Calvo M, Bachs O, Agell N. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J Biol Chem 2008;283:10621-31.
18. Bosch M, Gil J, Bachs O, Agell N. Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21(cip1). J Biol Chem 1998;273:22145-50.
19. Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O. The key role of calmodulin in KRAS-driven adenocarcinomas. Mol Cancer Res 2015;13:1265-73.
20. Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, et al. Calmodulin activates phosphatidylinositol 3-kinase. J Biol Chem 1997;272: 28183-6.
21. Liao J, Planchon SM, Wolfman JC, Wolfman A. Growth factor-dependent AKT activation and cell migration requires the function of c-K(B)-Ras versus other cellular ras isoforms. J Biol Chem 2006;281:29730-8.
22. Abraham SJ, Nolet RP, Calvert RJ, Anderson LM, Gaponenko V. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Biochemistry 2009;48:7575-83.
23. Drosten M, Lechuga CG, Barbacid M. Genetic analysis of Ras genes in epidermal development and tumorigenesis. Small GTPases 2013;4: 236-41.
24. Nussinov R, Tsai CJ, Mattos C. 'Pathway drug cocktail': targeting Ras signaling based on structural pathways. Trends Mol Med 2013;19: 695-704.
25. Baker TL, Zheng H, Walker J, Coloff JL, Buss JE. Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-ras. J Biol Chem 2003;278:19292-300.
26. Magee AI, Gutierrez L, McKay IA, Marshall CJ, Hall A. Dynamic fatty acylation of p21N-ras. EMBO J 1987;6:3353-7.
27. Ahearn IM, Tsai FD, Court H, Zhou M, Jennings BC, Ahmed M, et al. FKBP12 binds to acylated H-ras and promotes depalmitoylation.Mol Cell 2011;41:173-85.
28. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600-8.
29. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2011;2:216-31.
30. Schuhmacher AJ, Guerra C, Sauzeau V, Canamero M, Bustelo XR, Barbacid M. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 2008;118:2169-79.
31. Nishimura A, Linder ME. Identification of a novel prenyl and palmitoyl modification at the CaaX motif of Cdc42 that regulates RhoGDI binding. Mol Cell Biol 2013;33:1417-29.
32. Gentry LR, Nishimura A, Cox AD, Martin TD, Tsygankov D, Nishida M, et al. Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases. J Biol Chem 2015;290:22851-61.
33. Nussinov R, Jang H, Tsai CJ. The structural basis for cancer treatment decisions. Oncotarget 2014;5:7285-302.